Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer and influenza virus vaccines - ImmunityBio

Next Previous
Drug Profile

Research programme: cancer and influenza virus vaccines - ImmunityBio

Alternative Names: Breast cancer vaccine - ImmunityBio; Head and neck cancer vaccine - ImmunityBio; HER vaccine - ImmunityBio; HPV-H&N cancer vaccine - ImmunityBio; WT-1-targeted vaccine - ImmunityBio

Latest Information Update: 28 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Etubics Corporation
  • Developer ImmunityBio
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Head and neck cancer; Malignant melanoma

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
  • 08 Jan 2018 NantKwest plans the phase Ib/II QUILT-3.067 trial for Triple negative breast cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (NCT03387085)
  • 27 Dec 2017 National Cancer Institute plans a phase I trial for Prostate, Lung, Breast and Colon cancer (Late-stage disease) in USA , (NCT03384316)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top